Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data

BACKGROUND: While HIV, AIDS and atypical Mycobacterium infections are closely linked, the use of Integrase-Inhibitor based cART, notably raltegravir-based regimens is more widespread. RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidl...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :AIDS Res Ther
Главные авторы: Spinner, Christoph D, Wille, Florian, Schwerdtfeger, Christiane, Thies, Philipp, Tanase, Ursula, Von Figura, Guido, Schmid, Roland M, Heinz, Werner J, Klinker, Hartwig Hf
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2015
Предметы:
Short Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297374/
https://ncbi.nlm.nih.gov/pubmed/25598834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12981-014-0041-8
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы